US FTC Diagnoses Omicron Symptom: More Fraudulent COVID-19 Treatment Claims
Executive Summary
Agency says emergence of Omicron variant spurred marketers of products and services from peptide therapy to herbal remedies, and from nasal irrigation to intravenous drips to make false COVID-19 claims.
You may also be interested in...
Virus Prevention Claims For RhinoSystems’ Naväge Flushed In Nasal Irrigation Advertising Review
During NAD review, RhinoSystems stated it previously pulled some COVID-19 prevention claims NeilMed challenged and pulled remaining ads after review began. Both RhinoSystems, which markets Naväge brand, and NeilMed, offering a namesake brand, were warned in 2021 by FTC about COVID-19 ad claims.
Virus Prevention Claims For RhinoSystems’ Naväge Flushed In Nasal Irrigation Advertising Review
During NAD review, RhinoSystems stated it previously pulled some COVID-19 prevention claims NeilMed challenged and pulled remaining ads after review began. Both RhinoSystems, which markets Naväge brand, and NeilMed, offering a namesake brand, were warned in 2021 by FTC about COVID-19 ad claims.
Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use
CofixRx and Sensory Cloud are latest OTC nasal spray marketers FDA warned about fraudulent COVID-19 claims. While the others’ violations were limited to violative claims, CofixRx also warned the active ingredient in its spray is limited to topical use.